Clinical Trial Overview

This study is a Phase 1 clinical trial led by Guangdong Hengluo Pharmaceuticals, evaluating the safety and tolerability of the SHR-2173 injectable in patients with primary immune thrombocytopenia. Enrollment began on November 12, 2025, and the trial is currently in the recruitment phase.

Disease Background and Current Treatment Landscape

Primary immune thrombocytopenia is an autoimmune disorder in which platelets are destroyed, leading to a high risk of bleeding. Current therapies are limited to steroids, immunoglobulins, and thrombopoietin receptor agonists. These treatments are associated with significant adverse effects and do not guarantee complete remission, substantially impacting patients’ quality of life.

Potential Differentiators of SHR-2173

Although the precise mechanism of SHR-2173 has not yet been disclosed, the program focuses on confirming safety through multiple subcutaneous administrations. Subcutaneous injection offers greater patient convenience compared with intravenous delivery and may be advantageous for long‑term therapy. If the safety profile proves favorable, the program could progress to efficacy‑focused Phase 2 and Phase 3 trials.

Company and Market Impact

Guangdong Hengluo Pharmaceuticals is a rapidly growing Chinese biotech company, and entry into Phase 1 represents a critical milestone for showcasing its drug‑development capabilities. Successful trial execution could attract additional investment and partnership opportunities, strengthening its competitive position in the Chinese ITP therapeutic market. Conversely, any safety concerns could delay development timelines and necessitate resource reallocation across other pipeline assets.

Outlook and Regulatory Pathway

At present, the program is focused on safety data collection and is not yet positioned for regulatory approval. However, if early data are positive, the National Medical Products Administration (NMPA) may consider an early‑access program or accelerated review, which could serve as a springboard for eventual global market entry.